Diabetic kidney disease (DKD) is escalating and is the major cause of end stage kidney failure. There is increasing evidence to support the role of epigenetic factors and metabolic memory in linking the environmental and genetic causes of this disease. Although our understanding of this disease has improved, there has been no significant efficacious therapeutic translation in the last decade. Current sequencing technology has allowed interrogation of the human transcriptome. It is evident that although approximately 80% of the genome is transcribed, only 1–2% is read and coded into protein. The remaining non-coding RNA, historically assumed to be ‘junk’, is now known to have key roles in regulating gene function and orchestrate how and when coding genes are expressed. This largest subset of non-coding RNAs called long non-coding RNAs (LNCRNAs) drives epigenetic changes and has functional relevance best characterized in cancers and cardiovascular disease. This understanding, coupled with the availability and affordability of RNA sequencing, has shifted our therapeutic strategies towards genomic therapy in DKD. The role of LNCRNAs with respect to DKD is only just emerging. In this review we summarize the role of LNCRNAs in DKD and the existing antisense oligonucleotide therapy that may provide precise and targeted medicine to treat DKD in this postgenomic era.
Skip Nav Destination
Article navigation
September 2016
-
Cover Image
Cover Image
Corin protein expression in human renal proximal convoluted tubules as shown by brown staining in immunohistochemistry. See pp. 1655-1664 for further details. Image kindly provided by Qingyu Wu.
Review Article|
August 08 2016
Long non-coding RNAs–towards precision medicine in diabetic kidney disease?
Usha Panchapakesan;
*Renal Research Group, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, NSW 2065, Australia
Correspondence: Usha Panchapakesan (email usha.panchapakesan@sydney.edu.au).
Search for other works by this author on:
Carol Pollock
Carol Pollock
*Renal Research Group, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, NSW 2065, Australia
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
April 03 2016
Revision Received:
May 15 2016
Accepted:
May 31 2016
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2016 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society
2016
Clin Sci (Lond) (2016) 130 (18): 1599–1602.
Article history
Received:
April 03 2016
Revision Received:
May 15 2016
Accepted:
May 31 2016
Citation
Usha Panchapakesan, Carol Pollock; Long non-coding RNAs–towards precision medicine in diabetic kidney disease?. Clin Sci (Lond) 1 September 2016; 130 (18): 1599–1602. doi: https://doi.org/10.1042/CS20160261
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.